BIOCON Q2 FY27 Guidance vs Delivery (BIOCON Management Mirror)

H1 FY27 Revenue Delivery Against Progressive Scaling Guided in Mar'26 Qtr

In Sep'26 Qtr, Biocon reported consolidated operating revenue of INR 43,889 million (+2.2% YoY). The biopharmaceutical business grew 5% YoY, and H1 FY27 operating revenue reached Rs 8,725 crore (+6% YoY). This aligns with management's earlier guidance from the Mar'26 Qtr concall, which stated that H1 FY27 growth would be stable, aided by currency tailwinds, with meaningful acceleration back-ended toward H2. Management now expects H2 FY27 to be significantly stronger than H1 across all businesses, driven by accelerating biosimilars momentum, Generics profitability expansion, and sequential recovery at Syngene.